ReviewBioMed research international2019
Advances in Gut Microbiota of Viral Hepatitis Cirrhosis.
Review in BioMed research international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 52 citations in OpenAlex.
- Dynamic gut microbiota shift in chronic liver disease progression: machine learning models and the E/Er ratio as a predictive biomarker.Journal of translational medicine · 2026Article
- S100B in brain-gut-liver crosstalk: from glial activation to multiorgan inflammation.Frontiers in immunology · 2026Review
- The Role of Beneficial Microbiota in COVID-19: Insights from Key Bacterial Genera.Microorganisms · 2025Review
- Antibiotic resistance in patients with liver cirrhosis: Prevalence and current approach to tackle.World journal of clinical cases · 2023Review
- Gut Microbiota Combined with Metabolomics Reveal the Mechanisms of Sika Deer Antler Protein on Cisplatin-Induced Hepatorenal Injury in Mice.Molecules (Basel, Switzerland) · 2023Article
- Liver cirrhosis and complications from the perspective of dysbiosis.Frontiers in medicine · 2023Review
- Autoantibodies: are they a clue for liver diseases?Clinical and experimental hepatology · 2022Article
- Article
- Compositions of gut microbiota before and shortly after hepatitis C viral eradication by direct antiviral agents.Scientific reports · 2022Article
- Gut Microbiome and Organ Fibrosis.Nutrients · 2022Review
- Relationship between Intestinal Microflora and Hepatocellular Cancer Based on Gut-Liver Axis Theory.Contrast media & molecular imaging · 2022Review
- Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review.Seminars in liver disease · 2021Review
- The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development.Probiotics and antimicrobial proteins · 2021Review
- Is it time for microbiome-based therapies in viral infections?Virus research · 2021Review
- Intestinal Microbiota-A Promising Target for Antiviral Therapy?Frontiers in immunology · 2021Review
- Synbiotics Supplements Lower the Risk of Hand, Foot, and Mouth Disease in Children, Potentially by Providing Resistance to Gut Microbiota Dysbiosis.Frontiers in cellular and infection microbiology · 2021Article
- Alteration of Gut Microbiota and Its Impact on Immune Response in Patients with Chronic HBV Infection: A Review.Infection and drug resistance · 2021Review
- Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)?American journal of physiology. Endocrinology and metabolism · 2020Review
- Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection?Nutrients · 2020Review
- Viral Infections, the Microbiome, and Probiotics.Frontiers in cellular and infection microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although gut dysbiosis appears in 20%-75% of cirrhotic patients, there are limited data on microbiota profiles in viral hepatitis cirrhotics and its role in progression to cirrhosis. Further understanding on the relationship between gut dysbiosis and cirrhosis presents a unique opportunity in not only predicting the development of cirrhosis but also discovering new therapies. Recent advances have been made on identifying unique microbiota in viral hepatitis cirrhotics and adopting the microbiota index to predict cirrhosis. Therapeutic intervention with microbiome-modulating has been explored. Cirrhosis from viral infection has unique bacterial or fungal profiles, which include increased numbers of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.